Harrow (HROW) Retained Earnings (2010 - 2026)
Harrow's (HROW) quarterly Retained Earnings came in at $212.8 million in Q1 2026, up 225.79% year-on-year from $65.3 million in Q1 2025, and up 1.85% quarter-over-quarter from $208.9 million in Q4 2025.
Harrow (HROW) Retained Earnings (2010 - 2026) Analysis & Trends
Harrow's Retained Earnings history runs 17 years deep, the most recent figure standing at $212.8 million for Q1 2026.
- On a quarterly basis, Retained Earnings rose 225.79% year-over-year to $212.8 million in Q1 2026; TTM through Mar 2026 was $212.8 million, a 225.79% increase from a year earlier, with the FY2025 full-year figure at $208.9 million, down 5.46% from the prior year.
- Retained Earnings grew to $212.8 million in Q1 2026 per HROW's latest filing, from $208.9 million in the prior quarter.
- Across five years, Retained Earnings topped out at $221.0 million in Q4 2024 and bottomed at -$169.2 million in Q1 2025.
- The 5-year median for Retained Earnings is $142.7 million (2023), against an average of $64.9 million.
- Across the five-year window, Retained Earnings surged 281.35% in 2023 and tumbled 206.87% in 2024, its largest moves.
- Year by year, Retained Earnings stood at -$109.5 million in 2022, then retreated by 22.29% to -$133.9 million in 2023, then surged by 265.05% to $221.0 million in 2024, then decreased by 5.46% to $208.9 million in 2025, then climbed by 1.85% to $212.8 million in 2026.
- Per Business Quant, the three latest HROW Retained Earnings figures stand at $212.8 million (Q1 2026), $208.9 million (Q4 2025), and $210.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 37.04 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 28.20 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 1.11 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 4.54 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 8.83 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | -1.81 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 18.66 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 589.60 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -2.13 Bn |
| 10 | Harrow | 1.56 Bn | 1.47 Bn | 27.05 Mn | 212.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 212.80 Mn |
| Dec 31, 2025 | 208.93 Mn |
| Sep 30, 2025 | 210.13 Mn |
| Jun 30, 2025 | 213.79 Mn |
| Mar 31, 2025 | -169.17 Mn |
| Dec 31, 2024 | 221.00 Mn |
| Sep 30, 2024 | 216.10 Mn |
| Jun 30, 2024 | 212.44 Mn |
| Mar 31, 2024 | -147.47 Mn |
| Dec 31, 2023 | -133.90 Mn |
| Sep 30, 2023 | 200.48 Mn |
| Jun 30, 2023 | 142.74 Mn |
| Mar 31, 2023 | 137.99 Mn |
| Dec 31, 2022 | -109.49 Mn |
| Sep 30, 2022 | -110.55 Mn |
| Jun 30, 2022 | -104.08 Mn |
| Mar 31, 2022 | -97.85 Mn |
| Dec 31, 2021 | -95.41 Mn |
| Sep 30, 2021 | -87.99 Mn |
| Jun 30, 2021 | 102.84 Mn |